Previous studies have demonstrated that the hyperactivation of the PI3K/AKT pathway appeared in almost all advanced prostate cancers, mainly occurring through the loss of PTEN [8–11], which results in resistance to hormone therapy and poor prognosis [12]. The gene discussed is PTEN; the disease is prostate carcinoma.